The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
SWB:VX1
|
US |
|
S
|
Sysco Corp
SWB:SYY
|
US |
|
Foresight Group Holdings Ltd
F:9LR
|
GG |
|
T
|
Terumo Corp
F:TUO
|
JP |
|
H
|
Hikari Tsushin Inc
DUS:HIK
|
JP |
|
Y
|
Yue Yuen Industrial (Holdings) Ltd
F:YUE1
|
HK |
|
S
|
Sempra Energy
F:SE4
|
US |
|
CK Hutchison Holdings Ltd
OTC:CKHUY
|
HK |
|
European Lithium Ltd
ASX:EUR
|
AU |
|
C
|
Calbee Inc
F:9CB
|
JP |
|
Compagnie des Alpes SA
PAR:CDA
|
FR |
|
Japan Tobacco Inc
OTC:JAPAF
|
JP |
|
Bitmine Immersion Technologies Inc
NYSE:BMNR
|
US |
|
N
|
National Beverage Corp
F:20V
|
US |
|
M
|
Melco Resorts & Entertainment Ltd
F:MAS
|
HK |
|
M
|
Mineralbrunnen Ueberkingen-Teinach GmbH & Co KgaA
SWB:MUT
|
DE |
|
CK Hutchison Holdings Ltd
F:2CK
|
HK |
|
T
|
T Man Pharmaceutical PCL
SET:TMAN
|
TH |
|
C
|
Christian Dior SE
DUS:DIO
|
FR |
|
CAE Inc
TSX:CAE
|
CA |
|
Morguard Corp
TSX:MRC
|
CA |
|
Red Violet Inc
NASDAQ:RDVT
|
US |
|
F
|
First Financial Bankshares Inc
F:FI6
|
US |
|
Morguard Corp
F:74S
|
CA |
Vertex Pharmaceuticals Inc (VX1)’s 12-month stock price forecast through August 2027 has a consensus target of €506.26, implying 24% upside. The forecast is based on price targets from 29 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
VX1 is 506.26 EUR with a low forecast of 303.82 EUR and a high forecast of 606.43 EUR.
Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.
Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 8 years is 10%.
Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 47%. The projected CAGR for the next 3 years is 21%.
The compound annual growth rate for Net Income over the next 8 years is 14%.
AI-generated answers can contain mistakes, outdated facts, or incomplete information. Always verify important details before making decisions.
The AI Assistant is designed for research and education. It does not provide personalized investment, legal, or tax advice.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more